Thomas W P Friedl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4681035/publications.pdf

Version: 2024-02-01

99 papers 2,303 citations

331670 21 h-index 233421 45 g-index

104 all docs

104 docs citations

104 times ranked 3014 citing authors

#	Article	IF	CITATIONS
1	Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer—Reply. JAMA Oncology, 2022, 8, 171.	7.1	O
2	The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. British Journal of Cancer, 2022, 126, 1715-1724.	6.4	14
3	Fishing for (in)continence: long-term follow-up of women with OASIS–still a taboo. Archives of Gynecology and Obstetrics, 2021, 303, 987-997.	1.7	5
4	Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer. Mechanisms of Ageing and Development, 2021, 196, 111494.	4.6	4
5	Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment. JAMA Oncology, 2021, 7, 1149.	7.1	25
6	Sex-specific differences in DNA double-strand break repair of cycling human lymphocytes during aging. Aging, 2021, 13, 21066-21089.	3.1	14
7	Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB. Oncology, 2020, 98, 91-97.	1.9	20
8	Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancerâ€"results from the randomized phase III SUCCESS-A trial. Breast Cancer Research, 2020, 22, 111.	5.0	15
9	CT Scan in the Prediction of Lymph Node Involvement in Ovarian Cancer – a Retrospective Analysis of a Tertiary Gyneco-Oncological Unit. Geburtshilfe Und Frauenheilkunde, 2020, 80, 518-525.	1.8	12
10	The Association between Obesity and Premenopausal Breast Cancer According to Intrinsic Subtypes – a Systematic Review. Geburtshilfe Und Frauenheilkunde, 2020, 80, 601-610.	1.8	14
11	Lymph Node Ratio Can Better Predict Prognosis than Absolute Number of Positive Lymph Nodes in Operable Cervical Carcinoma. Oncology Research and Treatment, 2020, 43, 87-95.	1.2	7
12	53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients. Cancers, 2020, 12, 930.	3.7	7
13	Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. Clinical Breast Cancer, 2020, 20, 439-447.	2.4	3
14	Abstract OT3-18-01: Detect III/IV study trial - The multicenter study program in patients with HER2-negative MBC and circulating tumor cells. , 2020, , .		0
15	295â€Accumulation of 53BP1 in circulating tumor cells during treatment with eribulin identifies chemotherapy-responsive metastatic breast cancer patients. , 2020, , .		O
16	Abstract P4-01-01: Presence of circulating tumor cells in high-risk early breast cancer do not predict site of metastatic lesions - Results of the SUCCESS A trial. , 2020, , .		0
17	Abstract OT2-01-03: DETECT V - Comparison of dual HER2-targeted therapy with trastuzumab and pertuzumab plus CDK4/6 inhibition in combination with either chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer., 2020,,.		O
18	Response to Di Cosimo, Torri, and Porcu. Journal of the National Cancer Institute, 2019, 111, 1234-1235.	6.3	1

#	Article	IF	CITATIONS
19	Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. Cells, 2019, 8, 1412.	4.1	45
20	BRCA1 mislocalization leads to aberrant DNA damage response in heterozygous ABRAXAS1 mutation carrier cells. Human Molecular Genetics, 2019, 28, 4148-4160.	2.9	4
21	Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. Breast, 2019, 44, 81-89.	2.2	8
22	Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial. Breast Cancer Research and Treatment, 2019, 175, 627-635.	2.5	8
23	Emergency peripartal hysterectomy – a single-center analysis of the last 13 years at a tertiary perinatal care unit. Journal of Perinatal Medicine, 2019, 47, 169-175.	1.4	8
24	Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. Journal of the National Cancer Institute, 2019, 111, 380-387.	6.3	101
25	Prenatally Diagnosed Single Umbilical Artery (SUA) – Retrospective Analysis of 1169 Fetuses. Ultraschall in Der Medizin, 2019, 40, 221-229.	1.5	25
26	Comparison of preoperative serum VEGF in leiomyosarcoma and uterus myomatosus patients: A proof of concept study Journal of Clinical Oncology, 2019, 37, e17117-e17117.	1.6	1
27	A single-center retrospective analysis to evaluate the prognostic role of lymph node density in patients with lymph node-positive cervical cancer Journal of Clinical Oncology, 2019, 37, e17013-e17013.	1.6	0
28	Influence of the new FIGO classification for cervical cancer on patients' survival: Retrospective analysis of 265 histologically confirmed cases with FIGO stages Ia to Ilb Journal of Clinical Oncology, 2019, 37, e17006-e17006.	1.6	0
29	Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. Oncology Research and Treatment, 2018, 41, 93-98.	1.2	8
30	Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. JAMA Oncology, 2018, 4, e180163.	7.1	105
31	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. Clinical Breast Cancer, 2018, 18, 175-183.	2.4	21
32	Comparison of Fetomaternal Outcome between 47 Deliveries Following Successful External Cephalic Version for Breech Presentation and 7456 Deliveries Following Spontaneous Cephalic Presentation. Gynecologic and Obstetric Investigation, 2018, 83, 477-481.	1.6	1
33	Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years – Comparison of a University Center and a Community Hospital. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1138-1145.	1.8	2
34	Foetal Doppler Parameters as a Prognostic Marker Before Induction of Labour. Geburtshilfe Und Frauenheilkunde, 2018, 78, 859-865.	1.8	0
35	Seroma in breast surgery: all the surgeons fault?. Archives of Gynecology and Obstetrics, 2018, 298, 951-959.	1.7	26
36	Influence of Prognostic Factors on Lymph Node Involvement in Endometrial Cancer. International Journal of Gynecological Cancer, 2018, 28, 1145-1152.	2.5	10

#	Article	IF	CITATIONS
37	Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells—Results From the SUCCESS A Trial. Clinical Breast Cancer, 2018, 18, e1103-e1110.	2.4	0
38	Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients. BMC Cancer, 2018, 18, 141.	2.6	21
39	Prevalence of circulating tumor cells in early breast cancer patients 2 and 5Âyears after adjuvant treatment. Breast Cancer Research and Treatment, 2018, 171, 571-580.	2.5	12
40	Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial Journal of Clinical Oncology, 2018, 36, 515-515.	1.6	20
41	Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923) Journal of Clinical Oncology, 2018, 36, 522-522.	1.6	17
42	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. Clinical Breast Cancer, 2017, 17, 279-285.	2.4	10
43	Value of endometrial thickness assessed by transvaginal ultrasound for the prediction of endometrial cancer in patients with postmenopausal bleeding. Archives of Gynecology and Obstetrics, 2017, 296, 319-326.	1.7	18
44	Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?. Geburtshilfe Und Frauenheilkunde, 2017, 77, 1291-1298.	1.8	18
45	Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precision Oncology, 2017, 1, 1-12.	3.0	9
46	The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. PLoS ONE, 2017, 12, e0173593.	2.5	43
47	Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma. Oncotarget, 2017, 8, 98660-98676.	1.8	7
48	LKB1 and its importance for survival in EpCAM negative circulating tumor cells (CTC) in metastatic breast cancer Journal of Clinical Oncology, 2017, 35, e23061-e23061.	1.6	0
49	Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-Atrial. BMC Cancer, 2016, 16, 401.	2.6	14
50	Current role of liquid biopsy inÂmetastatic breast cancer and future perspectives. Der Gynakologe, 2016, 49, 680-684.	1.0	0
51	Predictors for a successful external cephalic version: a single centre experience. Archives of Gynecology and Obstetrics, 2016, 293, 749-755.	1.7	29
52	Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer $\hat{a} \in \text{``Results from the prospective multi-center randomized ADEBAR trial. Breast, 2016, 27, 69-77.}$	2.2	8
53	Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial. Geburtshilfe Und Frauenheilkunde, 2016, 76, 542-550.	1.8	7
54	Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?. Molecular Cancer, 2016, 15, 13.	19.2	46

#	Article	IF	CITATIONS
55	Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost. Archives of Gynecology and Obstetrics, 2016, 294, 861-866.	1.7	9
56	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research, 2016, 22, 2583-2593.	7.0	289
57	Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Archives of Gynecology and Obstetrics, 2016, 293, 271-281.	1.7	45
58	The DETECT study concept: Individualized therapy of metastatic breast cancer Journal of Clinical Oncology, 2016, 34, TPS634-TPS634.	1.6	6
59	Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer – The SUCCESS Trial. Anticancer Research, 2016, 36, 4771-4776.	1.1	11
60	Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer Journal of Clinical Oncology, 2016, 34, 11529-11529.	1.6	0
61	Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast Cancer. Translational Oncology, 2015, 8, 509-516.	3.7	17
62	Is open surgery the solution to avoid morcellation of uterine sarcomas? A systematic literature review on the effect of tumor morcellation and surgical techniques. Archives of Gynecology and Obstetrics, 2015, 292, 499-506.	1.7	12
63	Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer. Breast Cancer Research and Treatment, 2015, 151, 569-576.	2.5	40
64	The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Research, 2015, 17, 129.	5.0	93
65	Abstract OT1-2-03: The DETECT-study concept: Treatment based on the phenotype of circulating tumor cells in HER2-negative metastatic breast cancer. , 2015, , .		1
66	Abstract P4-11-21: Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study. , 2015, , .		1
67	Abstract P4-01-03: Prognostic relevance of circulating tumor cells across different molecular subgroups in the adjuvant SUCCESS-A study. , 2015, , .		0
68	Abstract P4-01-16: Detection of EMT, anoikis and stem cell markers in metastatic breast cancer patients under different lines of treatment., 2015 ,,.		1
69	Abstract P4-01-08: Persistence of circulating tumor cells immediately after and two years after systemic adjuvant chemotherapy in patients with early breast cancer – Results of the German SUCCESS trials. , 2015, , .		0
70	A novel approach to assess Her2-status of circulating tumour cells (CTCs) using the automated BioMarQ System Journal of Clinical Oncology, 2015, 33, e11615-e11615.	1.6	0
71	The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs) Journal of Clinical Oncology, 2015, 33, TPS11109-TPS11109.	1.6	0
72	Is seroma formation after breast conserving surgery influenced by intraoperative radiation therapy (IORT)?. Journal of Clinical Oncology, 2015, 33, e12049-e12049.	1.6	0

#	Article	IF	Citations
73	Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. Journal of the National Cancer Institute, 2014, 106, .	6.3	493
74	Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the randomized phase III SUCCESS-A study Journal of Clinical Oncology, 2014, 32, 1010-1010.	1.6	4
75	DETECT III/IV: Two combined clinical trials based on the phenotype of circulating tumor cells (CTCs) Journal of Clinical Oncology, 2014, 32, TPS11132-TPS11132.	1.6	1
76	The role of preoperative ultrasound evaluation of inguinal lymph nodes in patients with vulvar malignancy. Gynecologic Oncology, 2013, 131, 113-117.	1.4	34
77	Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC) Journal of Clinical Oncology, 2013, 31, e22075-e22075.	1.6	0
78	Biomarq: A novel approach to automated HER2-analysis of circulating tumor cells (CTCs) Journal of Clinical Oncology, 2013, 31, 638-638.	1.6	0
79	Discordance of the ER- and HER2-status on disseminated tumor cells (DTCs) compared to the primary tumor (PT) in patients with early breast cancer (BC) Journal of Clinical Oncology, 2013, 31, e22059-e22059.	1.6	0
80	Age-related variation in carotenoid-based plumage ornaments of male Red Bishops Euplectes orix. Journal of Ornithology, 2012, 153, 413-420.	1.1	13
81	A real-time PCR protocol for simple and fast quantification of blood parasite infections in evolutionary and ecological studies and some data on intensities of blood parasite infections in a subtropical weaverbird. Journal of Ornithology, 2012, 153, 239-247.	1.1	12
82	Experimentally elevated testosterone levels enhance courtship behaviour and territoriality but depress acquired immune response in Red Bishops <i>Euplectes orix</i> . Ibis, 2011, 153, 46-58.	1.9	26
83	Carotenoid-based plumage colouration in red bishops (Euplectes orix) — signalling presence rather than quality?. Behaviour, 2011, 148, 1372-1392.	0.8	5
84	Plumage Colouration, Age, Testosterone and Dominance in Male Red Bishops (<i>Euplectes orix</i>): A Laboratory Experiment. Ethology, 2010, 116, 806-820.	1.1	16
85	Male nest-building behaviour and mating success in the red bishop (Euplectes orix). Behaviour, 2009, 146, 771-794.	0.8	14
86	Within-pair young are more immunocompetent than extrapair young in mixed-paternity broods of the red bishop. Animal Behaviour, 2008, 75, 391-401.	1.9	10
87	Temporal changes in demand for and supply of nests in red bishops (Euplectes orix): dynamics of a biological market. Behavioral Ecology and Sociobiology, 2007, 61, 1369-1381.	1.4	16
88	Effects of behavioural time budgets and nest-building efficiency on male reproductive performance in red bishops (Euplectes orix). Journal of Ornithology, 2007, 148, 145-155.	1.1	7
89	Individual Male Calling Pattern and Male Mating Success in the European Treefrog (Hyla arborea): Is there Evidence for Directional or Stabilizing Selection on Male Calling Behaviour?. Ethology, 2006, 112, 116-126.	1.1	24
90	Sexual selection in the lek-breeding European treefrog: body size, chorus attendance, random mating and good genes. Animal Behaviour, 2005, 70, 1141-1154.	1.9	106

#	Article	IF	CITATIONS
91	Stress-dependent trade-off Between Immunological Condition and Reproductive Performance in the Polygynous Red Bishop (Euplectes orix). Evolutionary Ecology, 2005, 19, 221-239.	1.2	15
92	Extrapair Fertilizations in Red Bishops (Euplectes Orix): Do Females Follow Conditional Extrapair Strategies?. Auk, 2005, 122, 57-70.	1.4	11
93	EXTRAPAIR FERTILIZATIONS IN RED BISHOPS (EUPLECTES ORIX): DO FEMALES FOLLOW CONDITIONAL EXTRAPAIR STRATEGIES?. Auk, 2005, 122, 57.	1.4	9
94	Breeding success in a Red Bishop (Euplectes orix) colony in the Eastern Cape, South Africa, and its relation to nest site characteristics. Ostrich, 2004, 75, 95-105.	1.1	6
95	The effect of rainfall on the breeding behaviour of the Red Bishop,Euplectes orix. Ostrich, 2002, 73, 181-184.	1.1	11
96	THE VOCAL BEHAVIOUR OF MALE EUROPEAN TREEFROGS (HYLA ARBOREA): IMPLICATIONS FOR INTER- AND INTRASEXUAL SELECTION. Behaviour, 2002, 139, 113-136.	0.8	50
97	Nest and mate choice in the red bishop (Euplectes orix) : female settlement rules. Behavioral Ecology, 2000, 11, 378-386.	2.2	38
98	Determinants of male mating success in the red bishop (Euplectes orix). Behavioral Ecology and Sociobiology, 1999, 46, 387-399.	1.4	47
99	Individual quality and carotenoid-based plumage ornaments in male red bishops (Euplectes orix): plumage is not all that counts. Biological Journal of the Linnean Society, 0, 99, 384-397.	1.6	17